Effect of Weight Losing on the Improving Clinical Statement of Patients With Knee Osteoarthritis

Sadeghi, Alireza; Rad, Zahra Abbaspour; Sajedi, Behnam; Heydari, Amir Hossein; Akbarieh, Samira; Jafari, Behzad

doi:10.1016/j.reumae.2017.06.005

Cited by 2 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cardiovascular disease (CVD) is the most important cause of morbidity and mortality in diabetes mellitus (DM) patients [ 1 , 2 ]. Diabetic patients' chance of developing CVD is 2.5 folds more than nondiabetic patients [ 3 , 4 ]. Diabetic cardiomyopathy (DCM) is defined as heart failure unrelated to hypertension and coronary artery diseases.…”

Section: Introductionmentioning

confidence: 99%

Advanced Glycation End Product Blocker Drugs Have a Great Potential to Prevent Diabetic Cardiomyopathy in an Animal Model of Diabetes Mellitus Type-2

Heydari

Fathi

Heydari

et al. 2022

Cardiovascular Therapeutics

Self Cite

View full text Add to dashboard Cite

Introduction. Sphingosine 1 phosphate (S1P) is a product of the sphingosine kinase 1 (SphK1) enzyme. Increased S1P can lead to tissue fibrosis that is also one of the pathways for developing diabetic cardiomyopathy. Advanced glycation end products (AGEs) increase S1P in cells. The study is aimed at using aminoguanidine (AG) as an AGEs blocker drug to prevent diabetic cardiomyopathy. Materials and methods. 210 rats were enrolled in the study. Diabetes mellitus type-2 was induced, and rats were divided into AG treated diabetic and nondiabetic groups. The heart histology was assessed with Masson’s trichrome and hematoxylin-eosin staining. Cardiac function was measured with transthoracic echocardiography. S1P level and SphK1 gene expression were measured by western-blot and RT-qPCR, respectively. Results. Results showed that S1P level increases in diabetes, and its augmentation in cardiac tissue with K6PC-5 leads to cardiac fibrosis. 50 and 200 mg/kg of AG prevented cardiac fibrosis, but 100 mg/kg had no significant preventive effect. AG suppressed the SphK1 gene expression and reduced the fibrotic effect of S1P. AG preserved cardiac function by keeping ejection fraction and fractional shortening within the normal range in diabetic rats. Conclusion. AG has a suppressor effect on SphK1 gene expression besides its AGEs blocker role. AG is a potential drug to use in diabetic patients for preventing the development of diabetic cardiomyopathy. Other drugs that have AGEs or S1P blocker effects are a good choice for diabetic cardiomyopathy prevention.

show abstract

Section: Introductionmentioning

confidence: 99%

Advanced Glycation End Product Blocker Drugs Have a Great Potential to Prevent Diabetic Cardiomyopathy in an Animal Model of Diabetes Mellitus Type-2

Heydari

Fathi

Heydari

et al. 2022

Cardiovascular Therapeutics

Self Cite

View full text Add to dashboard Cite

show abstract

Behavioral weight loss interventions for people with physical disabilities: A systematic review

Hossaini,

Osmani,

Klug

2024

Obesity Reviews

View full text Add to dashboard Cite

SummaryAimThe aim of this study is to examine which interventions lead to clinically significant weight loss among people with physical disabilities.MethodsWe systematically searched three electronic databases (PubMed, Scopus, and CENTRAL) including studies until May 2022 to find randomized controlled trials on behavioral interventions and weight‐related outcomes in people with physical disabilities. Pharmacological or surgical interventions were excluded. Study quality was evaluated using the Cochrane Risk of Bias Tool. Interventions were grouped as dietary, physical activity, education/coaching, or multi‐component. Mean weight changes, standard deviations, confidence intervals, and effect sizes were extracted or calculated for assessment of the intervention effect.ResultsSixty studies involving 6,511 participants were included in the qualitative synthesis. Most studies (n = 32) included multi‐component interventions, incorporating dietary and physical activity components. Limited evidence suggests that extensive dietary interventions or long‐term multi‐component interventions might lead to a clinically relevant weight reduction of at least 5% for older individuals (age > 50) with mild‐to‐moderate mobility impairments.DiscussionDue to the high heterogeneity of studies and low study quality, it can be assumed that the range of applicability of the findings is questionable. Further research should examine younger age groups (i.e., children, adolescents, and adults under 40 years) and compare different settings such as schools, clinics, nursing homes, and assisted living facilities.

show abstract

Effect of Weight Losing on the Improving Clinical Statement of Patients With Knee Osteoarthritis

Cited by 2 publications

References 13 publications

Advanced Glycation End Product Blocker Drugs Have a Great Potential to Prevent Diabetic Cardiomyopathy in an Animal Model of Diabetes Mellitus Type-2

Advanced Glycation End Product Blocker Drugs Have a Great Potential to Prevent Diabetic Cardiomyopathy in an Animal Model of Diabetes Mellitus Type-2

Behavioral weight loss interventions for people with physical disabilities: A systematic review

Contact Info

Product

Resources

About